Free Trial

Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics logo
$8.18 -0.41 (-4.77%)
(As of 11/15/2024 ET)
TD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have give
Iovance Biotherapeutics, Inc. stock logo
Principal Financial Group Inc. Purchases 1,496,941 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Principal Financial Group Inc. boosted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 59.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,033,184 shares of the biotechnology
Iovance Biotherapeutics, Inc. stock logo
HC Wainwright Has Positive Estimate for IOVA FY2027 Earnings
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Friday, November 8th. HC Wainwright analyst J. Pantginis now expects that the biotec
Research Analysts Issue Forecasts for IOVA Q3 Earnings
Iovance Biotherapeutics’ Strong Q3 2024 Performance
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's Why
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's Why
Iovance Biotherapeutics, Inc. stock logo
Q3 Earnings Estimate for IOVA Issued By HC Wainwright
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Iovance Biotherapeutics in a report issued on Tuesday, November 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology c
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Wednesday.
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday
Iovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.
Iovance Biotherapeutics initiated with a Buy at UBS
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.5% - Time to Buy?
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 6.5% Higher - Still a Buy?
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (NASDAQ:IOVA) Research Coverage Started at UBS Group
UBS Group initiated coverage on Iovance Biotherapeutics in a report on Thursday. They set a "buy" rating and a $17.00 target price on the stock.
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% - Should You Buy?
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% - Should You Buy?
Iovance Biotherapeutics, Inc. stock logo
Sei Investments Co. Trims Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Sei Investments Co. decreased its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 14.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,761 shares of the biotechnology company's stock after se
High Growth Tech Stocks to Watch in October 2024
Is Iovance Biotherapeutics Stock a Buy?
Iovance Biotherapeutics: Moving To The Next Phase
Iovance Biotherapeutics, Inc. stock logo
Squarepoint Ops LLC Takes $2.07 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Squarepoint Ops LLC purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 257,543 shares of the b
Iovance Biotherapeutics, Inc. stock logo
Perceptive Advisors LLC Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Perceptive Advisors LLC lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 34.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,933,142 shares of the biotechnology company's stock after acquiring an add
Iovance Biotherapeutics, Inc. stock logo
1,612,055 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Marshall Wace LLP
Marshall Wace LLP acquired a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,612,055 shares of the biotechnology company's
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Holdings Lifted by Long Focus Capital Management LLC
Long Focus Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 195.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,132,000 shares of
Perceptive Advisors LLC Acquires New Stake in Vapotherm Inc
Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

The Tesla Trade Is Back In Business (Ad)

If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.

Discover how to trade Tesla, simply follow this link here.

IOVA Media Mentions By Week

IOVA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IOVA
News Sentiment

0.66

0.55

Average
Medical
News Sentiment

IOVA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IOVA Articles
This Week

18

7

IOVA Articles
Average Week

Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:IOVA) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners